323results about "Anaesthetics" patented technology

The invention relates to the technical field of biological pharmacy, and discloses a QS-21 saponin adjuvant as well as a preparation method and application thereof, the adjuvant is a composite liposome and comprises a liposome skeleton composed of distearoyl phosphatidylcholine and cholesterol, and QS-21 saponin, monophosphoryl lipid A and a local anesthetic are jointly entrapped in the liposome skeleton. The problem that high reactogenicity and immunogenicity of potent adjuvants are difficult to consider at the same time is solved, the immunostimulation component and the pain inhibition component are jointly entrapped in the same nano-carrier, collaborative delivery in injection local is achieved, and therefore pain and swelling caused by the adjuvants are accurately inhibited. The co-entrapment structure avoids the potential inhibition effect of the free anesthetic on the immune system, the potent body fluid and cellular immune enhancement activity of the adjuvant is completely reserved, and a new technical scheme is provided for developing vaccines with high safety and strong immune efficacy.

Disclosed in the present invention are a benzodiazepine compound, a pharmaceutical composition and the use thereof. Specifically provided is a compound represented by formula I, or a stereoisomer thereof, a deuterated compound thereof, or a pharmaceutically acceptable salt thereof. The compound provided in the present invention has one or more of the following advantageous effects: (1) the compound of the present invention exhibits good intravenous sedative and anesthetic effects; (2) the compound of the present invention exhibits low drug accumulation and a good tolerance; and (3) the compound of the present invention achieves an anesthetic effect with faster recovery.

The invention provides a heterocyclic compound and a pharmaceutical composition and application thereof, and belongs to the technical field of pharmaceutical chemistry. The series of heterocyclic compounds prepared by the invention have efficient sedative, hypnotic and / or anesthetic effects, can control the state of epilepsy, also have an analgesic effect, and have great significance for clinically preparing drugs with the analgesic effect and drugs with anesthetic, sedative, hypnotic and / or capable of controlling the state of epilepsy. The invention provides a new choice for the medicine which has the effects of anesthesia, sedation and hypnosis and / or can control epilepsy persistence and also has an analgesic effect.

The invention discloses a novel compound rapid surface anesthetic and a preparation method thereof, and belongs to the field of pharmaceutical preparations. According to the anesthetic, core anesthetic components of lidocaine and tetracaine are compounded with propylene glycol-laurocapram synergistic penetration enhancer, menthol auxiliary penetration enhancer, carbomer 980 gel matrix, triethanolamine pH regulator, glycerol humectant, panthenol soothing agent, purified water and the like, a surface smearing agent is prepared through a specific process, and the anesthetic can be administered in combination with an iontophoresis technology. Compared with the existing surface anesthetic for the cosmetic surgery, the surface anesthetic disclosed by the invention solves the problems of slow effect taking and poor effect, can realize rapid penetration of local skin, has short anesthesia effect taking time, long duration and good effect, has no obvious irritation to the skin, has good product stability, can effectively reduce the drug toxicity, and has a good application prospect. The device is suitable for surface anesthesia of non-surgical medical beauty items such as skin beauty, laser treatment and water-light micro-needles.

This invention provides a novel GABA structure with better efficacy, reduced side effects, and greater safety for clinical use. A This invention relates to receptor agonists, specifically a phenol derivative, its preparation method, and its use in the central nervous system. The phenol derivative provided by this invention offers more and better drug options for inducing or maintaining anesthesia in animals or humans, promoting sedation and hypnosis, and treating and / or preventing anxiety, nausea, vomiting, migraines, seizures, epilepsy, neurodegenerative diseases, and other central nervous system-related disorders.

The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents,5 and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and / or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a 10 third antagonist comprising (1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-2-(1- methylethyl)cyclohexanecarboxamide (WS-12).

This invention relates to the field of biopharmaceutical technology, disclosing a QS-21 saponin adjuvant, its preparation method, and its applications. The adjuvant is a composite liposome comprising a liposome backbone composed of distearate phosphatidylcholine and cholesterol, with QS-21 saponin, monophosphatidyllipid A, and a local anesthetic co-encapsulated therein. This invention solves the common problem of high reactivity and immunogenicity in potent adjuvants by co-encapsulating immunostimulatory and analgesic components on the same nanocarrier, achieving synergistic delivery at the injection site, thereby precisely inhibiting adjuvant-induced pain and swelling. This co-encapsulation structure avoids the potential inhibitory effect of free anesthetics on the immune system, fully preserving the adjuvant's potent humoral and cellular immune-enhancing activity. This invention provides a new technical solution for developing vaccines with both high safety and strong immunogenicity.

The present application provides a quaternary ammonium salt compound and its preparation method and use. The compound is represented by the general formula (I), or its isomers, pharmaceutical salts, and compositions thereof can be used to prepare anesthetic or analgesic drugs. Each substituent in the general formula (I) is as defined in the specification. [Formula 1] TIFF2024519944000085.tif31143

In view of the health and addiction risks associated with opiates, anesthetic emulsions are described herein comprising eutectic mixtures of local anesthetics. In some embodiments, the anesthetic emulsions release one or more local anesthetics over a period of several days for continuous pain relief. An anesthetic emulsion, in some embodiments, comprises a dispersed phase comprising a eutectic mixture of lidocaine and benzocaine, and an aqueous or aqueous- based continuous phase comprising bupivacaine.

The present invention provides a composition comprising at least one N-acetylcysteine ​​and at least one nicotinamide riboside for use in a method for preventing and / or treating a neurological disease and / or condition. In one embodiment of the present invention, the composition maintains or improves brain function, particularly brain energy deficiency. In another embodiment of the present invention, the composition improves neurological recovery and regeneration after injury or surgery. In another embodiment of the present invention, the composition can be used in a method for preventing and / or treating a neurological disease and / or condition, and / or a method for recovery after injury or surgery.

Pharmaceutical combinations of etomidate derivatives and propofol and pharmaceutical compositions thereof for use in anesthesia, sedation and / or hypnosis of animals or humans. The pharmaceutical composition of the etomidate derivative and the propofol or the pharmaceutical composition of the etomidate derivative and the propofol shows an excellent synergistic effect compared with independent administration and combined administration.

Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.

A handheld electronic drug-requesting device includes a handle configured to be grasped by a patient's hand, a display embedded into the handle, and a touch-activated control integrated in the handle or the display. The handheld device performs operations that include determining the device is electronically coupled to a drug-delivery device for delivery of a drug to the patient and, in response to determining the device is electronically coupled to the drug-delivery device, receiving information related to a patient profile associated with the patient, presenting a user interface element on the display to the patient including the information related to the patient profile associated with the patient, receiving a patient request to deliver a dose of the drug to the patient via the touch-activated control, and, responsive to the patient request, causing the dose of the drug to be delivered.

The application belongs to the technical field of biological medicine, and particularly relates to a composite material containing a local anesthetic and a preparation method thereof. The composite material containing the local anesthetic comprises the following raw materials in parts by weight: bupivacaine hydrochloride 10-15 parts, a light-heat conversion agent 4-8 parts, delta-cadinene 0.5-1 part, a penetration enhancer 1-3 parts, and glycerol 2-5 parts. The light-heat conversion agent and the bupivacaine hydrochloride are added in combination, so that the discomfort caused by photothermal therapy is relieved. The delta-cadinene and the bupivacaine hydrochloride are combined, so that the analgesic effect is improved, the analgesic time is prolonged, the pain caused by frequent dressing change is avoided, and the toxic side effects caused by the accumulation of blood drug concentration are avoided. In addition, the penetration enhancer composed of egg membrane protein peptide and polylysine is introduced, so that the absorption of the effective components by the skin is further promoted, and the analgesic effect is quickly exerted.

In view of the health and addiction risks associated with opiates, anesthetic emulsions are described herein comprising eutectic mixtures of local anesthetics. In some embodiments, the anesthetic emulsions release one or more local anesthetics over a period of several days for continuous pain relief. An anesthetic emulsion, in some embodiments, comprises a dispersed phase comprising a eutectic mixture of menthol lidocaine and benzocaine, and an aqueous or aqueous-based continuous phase comprising bupivacaine.

A pharmaceutical combination of an etomidate derivative and ciprofol, and a pharmaceutical composition comprising the etomidate derivative and ciprofol. Use of the pharmaceutical combination or the pharmaceutical composition in anesthesia, sedation, and / or hypnosis of animals or humans. Compared to the administration of the etomidate derivative or ciprofol alone and the combined administration of etomidate and ciprofol, the pharmaceutical combination or the pharmaceutical composition shows an excellent synergistic effect, significantly improving the recovery time after anesthesia withdrawal, etc.

The invention discloses a compound with a local anesthesia function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method of the compound comprises the following steps: mixing and heating lidocaine and 2-bromoethanol to obtain a compound 1; the preparation method comprises the following steps: mixing dicarboxylic acid, N-hydroxysuccinimide, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and a solvent to obtain a mixed solution; mixing and dissolving a compound 1, alkali and a solvent, and then adding into the mixed solution; and then carrying out spin-drying, separation and purification to obtain the compound with the local anesthesia function. The medicine can be used as a local anesthetic or analgesic for long-acting nerve block or selective nerve block. The medicine can block nerve conduction, has biocompatibility and biodegradability, is expected to overcome the problems of short time efficiency of single-needle injection and the like, and improves the efficacy of the medicine.

The application relates to a film-forming composition containing an ionic liquid and a preparation method thereof, the film-forming composition is formed by a drug (API) with an active ingredient and a counter ion corresponding thereto or an API-ILs novel drug delivery system formed by two different API, can realize liquidization of a solid drug, improve the solubility, skin permeability and bioavailability of a poorly soluble drug, prevent the drug from being precipitated due to drug supersaturation after the film-forming composition is formed into a film on the surface of the skin, meanwhile, the composition has a good plasticizing effect on a film-forming polymer without adding a plasticizer, and the use of the traditional plasticizer can be avoided, and safety hidden dangers and toxicity caused by the use of the traditional plasticizer can be avoided.

The invention relates to the technical field of biological medicines, in particular to a bupivacaine sustained-release injection as well as a preparation method and application thereof. The invention provides a bupivacaine drug compound. The bupivacaine drug compound contains an amide local anesthetic bupivacaine as an active component and a plurality of pharmaceutically acceptable slow-release carrier materials. The drug compound disclosed by the invention adopts a supramolecular synthesis strategy and is prepared into nano-particles through a self-assembly method of a molecular recognition mechanism between Ad and Cd. The novel bupivacaine nano-particles provided by the invention solve the problem of too fast release of the bupivacaine hydrochloride, the preparation method is simple, flexible and modularized, the nano-preparation with controllable carrier size, stable surface chemical property and high drug loading capacity is prepared, the slow release time in vivo can be prolonged, and the analgesic effect can be continuously exerted.

The invention relates to the technical field of gel preparations, in particular to ropivacaine phospholipid gel as well as a preparation method and application thereof. The invention provides ropivacaine phospholipid gel. The ropivacaine phospholipid gel is prepared from ropivacaine, mixed lipid and a hydration solvent, wherein the mixed lipid comprises neutral phospholipid, negative phospholipid and cholesterol, the neutral phospholipid comprises at least one of phosphatidylcholine and phosphatidylcholine derivatives, and the negative phospholipid is phosphatidic acid or phosphatidylglycerol. According to the ropivacaine phospholipid gel, the encapsulation effect and the release characteristic of the ropivacaine phospholipid gel are improved by improving phospholipid raw materials and a preparation process.

This invention discloses the application of low-concentration topical anesthetics in ophthalmic surgery, relating to the field of low-concentration topical anesthetic application technology, including the following specific application process: confirming the patient's basic surgical condition before administration; selecting anesthetic drugs and optimizing the administration concentration; performing administration according to the specific situation; real-time dynamic monitoring and adjustment of the administration dosage; gradually reducing the drug and transitioning to withdrawal. This invention improves drug safety and patient compliance while ensuring analgesic effects by optimizing anesthetic drug concentration and administration method. Furthermore, by using topical anesthetics at concentrations lower than conventional anesthetics for local administration after ophthalmic surgery, it can effectively relieve postoperative pain, discomfort, and foreign body sensation while significantly reducing toxic effects on corneal epithelial cells, reducing delayed corneal healing, dry eye, and corneal damage. It is effectively applicable to analgesia management after pterygium excision, refractive surgery, and other common ophthalmic surgeries, and has good clinical application value.

The present invention relates to a drug delivery composition using crosslinked hyaluronic acid, a manufacturing method therefor, and a pharmaceutical composition comprising the drug delivery composition and a drug and having a desired release behavior.

The present invention relates to a composition comprising a β-cyclodextrin polymer (a) and at least one compound (b) selected from mycolactones and their derivatives.

This invention belongs to the field of medical experimental technology, specifically relating to a dental pre-anesthesia device based on an edible matrix, its preparation method, and its application. The device includes a handheld stick, a sugar ball, and a receiving box with a through hole. The box contains a gel anesthetic, which consists of an outer layer of sustained-release gel matrix and an inner anesthetic gel unit. The sustained-release gel matrix is ​​made of gelatin, pectin, or sodium alginate and is ring-shaped to conform to tooth shape. The anesthetic gel unit contains components such as lidocaine hydrochloride, chitosan, and carbomer 980, exhibiting high adhesiveness. Preparation involves first obtaining the anesthetic gel unit, then encapsulating it with the sustained-release gel matrix and coating it with sugar, and finally assembling the device. This device, through its edible matrix and sugar coating, transforms the anesthesia process into a "candy-eating" experience, significantly reducing patient fear, precisely conforming to the teeth and gingival margin, preventing anesthetic leakage, and improving the safety and effectiveness of anesthesia, making it particularly suitable for pediatric dental pre-anesthesia.

The present application relates to a bupivacaine sustained-release gel injection and a preparation method and application thereof, the components of the bupivacaine sustained-release gel injection include bupivacaine, degradable polymer, alkaline adjuvant and biocompatible organic solvent.The bupivacaine sustained-release gel injection provided by the present application has higher drug loading and lower burst level, is convenient to administer, can prolong the release of the encapsulated bupivacaine to 5-7 days, has rapid onset, and can exert sustained analgesic effect in vivo.

To provide a nonaqueous carbon dioxide external preparation in single dosage form.SOLUTION: An external preparation comprises a paste base, carbonate, an acid and / or a substance which produces an acid by hydrolysis, and alcohol. By applying the external preparation to the skin, it is possible to readily achieve the unique effects of carbon dioxide. This renders the preparation beneficial.SELECTED DRAWING: None